U.S. markets closed

ChromaDex Corporation (CDXC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.73+1.15 (+12.00%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close9.58
Open9.71
Bid10.87 x 1800
Ask10.77 x 1000
Day's Range9.63 - 13.20
52 Week Range2.50 - 23.66
Volume7,209,584
Avg. Volume3,317,731
Market Cap710.572M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.38
Earnings DateMar 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
    Business Wire

    New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients

    ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19" were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.

  • ChromaDex Announces $25 Million Private Placement of Common Stock
    Business Wire

    ChromaDex Announces $25 Million Private Placement of Common Stock

    ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions. In connection with the investment, the Company agreed to sell 3,846,153 shares of its common stock at a per share price of $6.50, for gross proceeds of approximately $25.0 million.